Soligenix Inc. (NASDAQ:SNGX) Short Interest Down 92.6% in June

Soligenix Inc. (NASDAQ:SNGX) was the recipient of a large decrease in short interest during the month of June. As of June 15th, there was short interest totaling 479,055 shares, a decrease of 92.6% from the May 31st total of 6,514,042 shares. Currently, 3.3% of the shares of the stock are short sold. Based on an average daily trading volume, of 3,609,843 shares, the short-interest ratio is presently 0.1 days.

Soligenix Trading Up 1.0%

Shares of Soligenix stock opened at $0.40 on Friday. The firm has a market capitalization of $5.85 million, a PE ratio of -0.24 and a beta of 1.84. Soligenix has a 12 month low of $0.28 and a 12 month high of $6.23. The business’s 50-day moving average price is $0.61 and its 200-day moving average price is $1.03.

Soligenix (NASDAQ:SNGX) last released its earnings results on Friday, May 8th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.02. As a group, analysts predict that Soligenix will post -0.9 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Soligenix in a report on Tuesday, April 21st. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $6.00.

Institutional Investors Weigh In On Soligenix

A number of hedge funds have recently made changes to their positions in SNGX. XTX Topco Ltd purchased a new stake in shares of Soligenix in the 4th quarter valued at $37,000. StoneX Group Inc. purchased a new position in Soligenix in the 4th quarter worth $50,000. Jane Street Group LLC bought a new stake in Soligenix in the fourth quarter worth $51,000. Banco BTG Pactual S.A. bought a new stake in Soligenix in the third quarter worth $54,000. Finally, Virtu Financial LLC bought a new stake in Soligenix in the third quarter worth $59,000. 3.60% of the stock is currently owned by institutional investors.

Soligenix Company Profile

Soligenix, Inc is a clinical‐stage biopharmaceutical company focused on developing vaccines and therapeutics to address unmet medical needs in rare diseases and biodefense. The company leverages proprietary technologies to create novel vaccine adjuvants, small‐molecule innate defense regulators and photodynamic therapies aimed at improving patient outcomes in orphan indications and protecting public health against biological threats.

The company’s pipeline is organized into two core divisions.